Table 1.
Demographical, clinical, and motor phenotypes characteristic
| PSP-Cog (N = 9) | PSP-P (N = 13) | PSP-PGF (N = 7) | PSP-RS (N = 24) | Kruskal–Wallis ANOVA |
Cog vs. RS | Cog vs. P | PGF vs. P | PGF vs. RS | RS vs. P | Cog vs. PGF | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | IRQ 2.5–97.5 |
Median | IRQ 2.5–97.5 |
Median | IRQ 2.5–97.5 |
Median | IRQ 2.5–97.5 |
p value | |||||||
| Age (years) | 71 | 64–79 | 71 | 58–74 | 75 | 62–84 | 71 | 55.3–84 | |||||||
| Education (years) | 9.0 | 5–22 | 13 | 5–19 | 8 | 5–23 | 8 | 4–18 | |||||||
| Sex (M %) | 44.4% | 53.8% | 50.0% | 33.3% |
0.5443 0.1003 0.6451 0.6905 |
||||||||||
| Age at symptoms’ onset (years) | 69 | 61–71 | 66 | 54–71 | 67 | 57–78 | 67 | 52–81 | |||||||
| Disease duration (years.) | 4 | 3–8 | 4 | 3–7 | 5 | 3–8 | 4 | 3–8 | 0.3858 | ||||||
| MDS-UPDRS | |||||||||||||||
| Part III | 54 | 36–68 | 29 | 9–48 | 58 | 38–61 | 42 | 17–77 | 0.0029 | * | * | * | * | ||
| H&Y ≥ 3 | 55.6% | 53.8% | 66.7% | 91.3% | 0.0514 | ||||||||||
| PSP-rating Scale | |||||||||||||||
| Bulbar | 2 | 0–4 | 2.5 | 1–6 | 1.5 | 1–2 | 3.5 | 1–7 | 0.2985 | ||||||
| Gait and midline | 10 | 5–20 | 7 | 4–15 | 15 | 14–16 | 10.5 | 3–17 | 0.1363 | ||||||
| History | 8 | 5–16 | 4.5 | 3–13 | 6 | 5–7 | 8.5 | 4–19 | 0.1811 | ||||||
| Limb motor | 7 | 6–12 | 5.5 | 2–8 | 6 | 5–7 | 4.5 | 2–6 | 0.0141 | * | * | ||||
| Mentation | 6 | 0–11 | 0 | 0–1 | 1 | 0–2 | 3.5 | 1–6 | 0.0086 | * | * | * | |||
| Ocular motor | 9 | 6–13 | 7.5 | 3–12 | 5.5 | 2–9 | 8 | 2–14 | 0.5342 | ||||||
| Total score | 42 | 30–66 | 27.5 | 15–49 | 35 | 35–35 | 40 | 21–56 | 0.0963 | ||||||
| PDQ-8 | 10 | 0–16 | 9 | 2–22 | 8 | 4–9 | 11 | 4–24 | 0.3221 | ||||||
| IADL | 2 | 0–8 | 5 | 2–8 | 5 | 1–8 | 4 | 1–8 | 0.039 | * | |||||
| ADL | 2 | 0–6 | 5 | 2–6 | 3.5 | 2–6 | 4 | 1–6 | 0.054 | * | |||||
| PDCFRS | 17 | 1–21 | 3 | 0–7 | 2 | 1–19 | 7 | 3–13 | 0.012 | * | * | * | * | ||
| MoCA (corr. score) | 14.98 | 7–25.0 | 20.7 | 18.7–27.7 | 21.4 | 15.9–24.1 | 19.9 | 13.4–28.4 | 0.008 | * | * | * | |||
| MMSE (corr. score) | 21 | 7–30 | 26.3 | 13.7–30.0 | 25 | 19.7–27.7 | 25.3 | 11.55–30.0 | 0.054 | ||||||
| CNT/MCI/dementia (%) | 11.1/55.6/33.3 | 38.5/61.5/0 | 16.7/83.3/0 | 12.5/70.8/16.7 | 0.1575 | ||||||||||
PSP phenotypes were defined based on predominant symptoms at onset. In particular, PSP-Cog included patients with predominant cognitive manifestation at onset
Bold values indicate statistically significant p values
MDS-UPDRS MDS-Unified Parkinson’s Disease Rating Scale, PDQ-8 Parkinson’s Disease Quality of Life Questionnaire 8-item scale, IADL Instrumental Activities of Daily Living scale, ADL Activities of Daily Living scale, PDCFRS Parkinson’s disease cognitive functional rating scale, MoCA Montreal Cognitive Assessment scale, MMSE Mini-Mental State Examination, CNT preserved cognitive status, MCI PD with mild cognitive decline